Source: GlobalData
Adaptive deep brain stimulation holds potential to transform Parkinson’s disease treatment, says GlobalData
Posted in Medical Devices
Two recent UC San Francisco studies have shown that adaptive deep brain stimulation (aDBS) offers personalized, 24/7 care for Parkinson’s disease through an implanted device. Unlike regular DBS, which delivers constant pulses, aDBS uses AI to monitor brain activity and adjust treatment based on symptom fluctuations. This marks a major advancement in the management of Parkinson’s disease, reflecting the growing impact of digital health technologies on patient care, according to GlobalData, a leading data and analytics company.
According to GlobalData, the global market for neurological devices was valued at $12.5 billion in 2023 and is expected to grow by a compound annual growth rate (CAGR) of 4.60% to reach $20.9 billion by 2033. This growth underscores the increasing importance and demand for advanced diagnostic and monitoring technologies in neurology, including those targeting Parkinson’s disease.
Cynthia Stinchcombe, Medical Devices Analyst at GlobalData, comments: “The market for neurological devices is witnessing significant growth and diversification. The increasing integration of advanced technology in the management of neurological disorders fits into the broader industry shift towards precision medicine, as reflected in the FDA’s recent push for innovative solutions in Parkinson’s disease management.”
UC San Francisco studies from 2023 and 2024 show that aDBS, a self-adjusting brain implant, can improve movement and sleep for Parkinson’s patients. Using AI-driven technology, the device monitors brain activity and delivers precise electrical pulses to alleviate symptoms in real-time. In trials, it reduced symptoms by 50%, with results published in August 2024, highlighting its potential for long-term Parkinson’s management.
GlobalData projects that with the continuous advancements in technology and the introduction of innovative therapies, the landscape of neurological devices is set to transform, offering new hope to millions affected by neurological diseases such as Parkinson’s.
Stinchcombe adds: “The integration of innovative medical technologies emphasizes the crucial role of advancements in contemporary healthcare. As the landscape of medical treatment evolves, particularly with these sophisticated systems, a promising shift is being witnessed towards more personalized and effective treatment strategies for neurological conditions.”
GlobalData’s analysis reflects the recent emphasis on wearable technologies and digital health apps—such as those leveraging Apple Watch data to monitor Parkinson’s symptoms—indicating a parallel innovation trajectory. While wearable technologies facilitate continuous monitoring outside clinical settings, sophisticated tools like Boston Scientific’s software enhance therapeutic interventions, offering a holistic approach to disease management.
Stinchcombe concludes: “In the face of an aging population and a rising incidence of Parkinson’s disease, the advancements being witnessed are encouraging for those affected. As the industry continues to focus on both proven and novel solutions, emerging technologies are pivotal in broadening the horizons of neurology diagnostics and improving patient outcomes. Together with the FDA’s initiative to enhance AI-driven diagnostics, these advancements are poised to dramatically improve the landscape of neurology.”